Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists01:23

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

204
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
204
Glucose Transporters01:27

Glucose Transporters

22.4K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Synthesis and Biological Characterization of 4,4-Difluoro-3-(phenoxymethyl)piperidine Scaffold as Dopamine 4 Receptor (D<sub>4</sub>R) Antagonist in vitro Tool compounds.

ChemMedChem·2025
Same author

End-to-End Backbone Cyclization Enhances Passive Permeability of bRo5 Oligomeric Depsipeptides with Nonlinear Size Dependence.

ACS medicinal chemistry letters·2025
Same author

Further Structure-Activity Relationship of G Protein-Gated Inwardly Rectifying Potassium Channels 1/2 Activators: Synthesis and Biological Characterization of In Vitro Tool Compounds.

ChemMedChem·2025
Same author

Synthesis and pharmacological evaluation of heteroarylamide derivatives as potential analgesic, anti-inflammatory, antidiarrheal and cytotoxic agents.

Heliyon·2024
Same author

Discovery of VU0467319: an M<sub>1</sub> Positive Allosteric Modulator Candidate That Advanced into Clinical Trials.

ACS chemical neuroscience·2024
Same author

The backbone constitution drives passive permeability independent of side chains in depsipeptide and peptide macrocycles inspired by <i>ent</i>-verticilide.

Chemical science·2024

Related Experiment Video

Updated: May 28, 2025

Multi-photon Intracellular Sodium Imaging Combined with UV-mediated Focal Uncaging of Glutamate in CA1 Pyramidal Neurons
10:29

Multi-photon Intracellular Sodium Imaging Combined with UV-mediated Focal Uncaging of Glutamate in CA1 Pyramidal Neurons

Published on: October 8, 2014

14.0K

Update on mGlu4 modulator patents: 2017 to present.

Fahad Imtiaz Rahman1,2, Thomas M Webster1, Corey R Hopkins1,3

  • 1Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE, USA.

Expert Opinion on Therapeutic Patents
|February 13, 2025
PubMed
Summary

Positive allosteric modulators (PAMs) targeting metabotropic glutamate receptor 4 (mGluR4) show potential for treating brain disorders. Clinical trial results for mGluR4 PAMs are crucial for future therapeutic development.

Keywords:
Parkinson’s diseaseallosteric modulationclinical trialsmGlur4metabotropic glutamate receptorpositive allosteric mod

More Related Videos

A High-throughput Calcium-flux Assay to Study NMDA-receptors with Sensitivity to Glycine/D-serine and Glutamate
04:48

A High-throughput Calcium-flux Assay to Study NMDA-receptors with Sensitivity to Glycine/D-serine and Glutamate

Published on: July 10, 2018

9.2K
Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
07:16

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

13.6K

Related Experiment Videos

Last Updated: May 28, 2025

Multi-photon Intracellular Sodium Imaging Combined with UV-mediated Focal Uncaging of Glutamate in CA1 Pyramidal Neurons
10:29

Multi-photon Intracellular Sodium Imaging Combined with UV-mediated Focal Uncaging of Glutamate in CA1 Pyramidal Neurons

Published on: October 8, 2014

14.0K
A High-throughput Calcium-flux Assay to Study NMDA-receptors with Sensitivity to Glycine/D-serine and Glutamate
04:48

A High-throughput Calcium-flux Assay to Study NMDA-receptors with Sensitivity to Glycine/D-serine and Glutamate

Published on: July 10, 2018

9.2K
Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
07:16

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

13.6K

Area of Science:

  • Neuroscience
  • Pharmacology
  • Drug Discovery

Background:

  • Metabotropic glutamate receptor 4 (mGluR4) plays a role in neurotransmitter release and synaptic plasticity.
  • Dysregulation of mGluR4 is linked to neurodegenerative disorders, psychiatric conditions, and other brain disorders.
  • mGluR4 is an emerging therapeutic target for conditions such as Parkinson's disease, multiple sclerosis, and chronic pain.

Purpose of the Study:

  • To review patents and literature on mGluR4 positive allosteric modulators (PAMs) from 2017 to 2024.
  • To summarize key exemplified compounds, structure-activity relationships (SAR), and biological data.
  • To discuss key findings and future directions for mGluR4 PAM development.

Main Methods:

  • Literature and patent searches using SciFinder, Google Patents, and PubMed.
  • Analysis of exemplified compounds, SAR, and biological data from retrieved sources.
  • Synthesis of findings to assess the current state and future prospects of mGluR4 PAMs.

Main Results:

  • Several mGluR4 PAMs have been exemplified in patents and literature.
  • Two compounds have progressed to early-stage clinical trials.
  • One clinical trial (Prexton Therapeutics) failed due to efficacy issues; results from another (Appello Pharmaceuticals) are pending.

Conclusions:

  • mGluR4 PAMs represent a promising therapeutic strategy for various neurological and psychiatric conditions.
  • The outcome of ongoing clinical trials will be critical in determining the future of mGluR4 PAMs in drug development.
  • Further research and development are needed to overcome efficacy challenges and advance mGluR4-targeted therapies.